Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 2,519,501	$ 9,080,426
Prepaid research and development	138,838	525,532
Other current assets	132,766	207,171
Total current assets	2,791,105	9,813,129
Deposits	145,137	127,534
Property and equipment, net	18,663	19,373
Right of use asset	371,308	315,932
Total assets	3,326,213	10,275,968
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	1,631,597	1,350,793
Accrued expenses	2,020,571	1,609,535
Lease liability, current portion	222,336	331,152
Short-term milestone payable due to Patagonia Pharmaceuticals LLC	1,750,000	1,750,000
Total current liabilities	5,624,504	5,041,480
Lease liability	322,793	0
Total liabilities	5,947,297	5,041,480
Commitments and contingencies (Note 7)
Preferred stock par value $0.001; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	0	0
Common stock, par value $0.001; 450,000,000 shares authorized; 3,047,431 shares issued and outstanding as of June 30, 2023, and 2,969,272 shares issued and outstanding as of December 31, 2022	148,432	148,354
Additional paid-in capital	53,619,078	53,350,126
Accumulated deficit	(56,388,594)	(48,263,992)
Total stockholders' (deficit) equity	(2,621,084)	5,234,488
Total liabilities and stockholders' (deficit) equity	$ 3,326,213	$ 10,275,968